|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||||||
| Brief Title † | 506U78 in Treating Patients With Refractory Hematologic Cancer | ||||||||
| Official Title † | A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies - POG/CCG Intergroup Study | ||||||||
| Brief Summary | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. |
||||||||
| Detailed Description | OBJECTIVES:
OUTLINE: Patients are stratified according to disease characteristics:
Group 1
Groups 2 and 4
Group 3
PROJECTED ACCRUAL: A maximum of 148 patients (37 patients per stratum) will be accrued for this study. |
||||||||
| Study Phase | Phase II | ||||||||
| Study Type † | Interventional | ||||||||
| Study Design † | Treatment | ||||||||
| Primary Outcome Measure † | |||||||||
| Secondary Outcome Measure † | |||||||||
| Condition † | Leukemia Lymphoma |
||||||||
| Intervention † | Drug: cytarabine Drug: methotrexate Drug: nelarabine Drug: therapeutic hydrocortisone |
||||||||
| MEDLINE PMIDs | |||||||||
| Links | Clinical trial summary from the National Cancer Institute's PDQ® database ![]() |
||||||||
| Recruitment Information Fields | |||||||||
| Recruitment Status † | Active, not recruiting | ||||||||
| Enrollment † | 148 | ||||||||
| Start Date † | June 1997 | ||||||||
| Completion Date | |||||||||
| Eligibility Criteria † | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY: Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
|
||||||||
| Gender | Both | ||||||||
| Ages | up to 21 Years | ||||||||
| Accepts Healthy Volunteers | No | ||||||||
| Contacts †† | |||||||||
| Location Countries † | United States, Canada, Switzerland | ||||||||
| Administrative Information Fields | |||||||||
| NCT ID † | NCT00002970 | ||||||||
| Organization ID | CDR0000065478 | ||||||||
| Secondary IDs †† | POG-9673, CCG-P9673 | ||||||||
| Study Sponsor † | Pediatric Oncology Group | ||||||||
| Collaborators †† | National Cancer Institute (NCI) Children's Cancer Group |
||||||||
| Investigators † |
|
||||||||
| Information Provided By | National Cancer Institute (NCI) | ||||||||
| Verification Date | October 2007 | ||||||||
| First Received Date † | November 1, 1999 | ||||||||
| Last Updated Date | July 23, 2008 | ||||||||